JP2017507139A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507139A5
JP2017507139A5 JP2016552595A JP2016552595A JP2017507139A5 JP 2017507139 A5 JP2017507139 A5 JP 2017507139A5 JP 2016552595 A JP2016552595 A JP 2016552595A JP 2016552595 A JP2016552595 A JP 2016552595A JP 2017507139 A5 JP2017507139 A5 JP 2017507139A5
Authority
JP
Japan
Prior art keywords
maintenance doses
antagonist
laba
ics
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016552595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507139A (ja
JP6673840B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/016852 external-priority patent/WO2015127229A1/en
Publication of JP2017507139A publication Critical patent/JP2017507139A/ja
Publication of JP2017507139A5 publication Critical patent/JP2017507139A5/ja
Priority to JP2020036331A priority Critical patent/JP6893265B2/ja
Application granted granted Critical
Publication of JP6673840B2 publication Critical patent/JP6673840B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016552595A 2014-02-21 2015-02-20 Il−4r拮抗薬の投与により喘息を処置または予防するための方法 Active JP6673840B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020036331A JP6893265B2 (ja) 2014-02-21 2020-03-04 Il−4r拮抗薬の投与により喘息を処置または予防するための方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461943019P 2014-02-21 2014-02-21
US61/943,019 2014-02-21
EP14306413 2014-09-15
EP14306413.7 2014-09-15
US201462077669P 2014-11-10 2014-11-10
US62/077,669 2014-11-10
PCT/US2015/016852 WO2015127229A1 (en) 2014-02-21 2015-02-20 Methods for treating or preventing asthma by administering an il-4r antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020036331A Division JP6893265B2 (ja) 2014-02-21 2020-03-04 Il−4r拮抗薬の投与により喘息を処置または予防するための方法

Publications (3)

Publication Number Publication Date
JP2017507139A JP2017507139A (ja) 2017-03-16
JP2017507139A5 true JP2017507139A5 (cg-RX-API-DMAC7.html) 2018-03-22
JP6673840B2 JP6673840B2 (ja) 2020-03-25

Family

ID=51570453

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016552595A Active JP6673840B2 (ja) 2014-02-21 2015-02-20 Il−4r拮抗薬の投与により喘息を処置または予防するための方法
JP2023139455A Active JP7636487B2 (ja) 2014-02-21 2023-08-30 Il-4r拮抗薬の投与により喘息を処置または予防するための方法
JP2025020415A Pending JP2025072593A (ja) 2014-02-21 2025-02-12 Il-4r拮抗薬の投与により喘息を処置または予防するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023139455A Active JP7636487B2 (ja) 2014-02-21 2023-08-30 Il-4r拮抗薬の投与により喘息を処置または予防するための方法
JP2025020415A Pending JP2025072593A (ja) 2014-02-21 2025-02-12 Il-4r拮抗薬の投与により喘息を処置または予防するための方法

Country Status (15)

Country Link
US (3) US10137193B2 (cg-RX-API-DMAC7.html)
EP (3) EP3973987B1 (cg-RX-API-DMAC7.html)
JP (3) JP6673840B2 (cg-RX-API-DMAC7.html)
KR (4) KR20230167770A (cg-RX-API-DMAC7.html)
CN (1) CN106232140A (cg-RX-API-DMAC7.html)
AU (3) AU2015218808B2 (cg-RX-API-DMAC7.html)
CA (1) CA2940295A1 (cg-RX-API-DMAC7.html)
ES (2) ES2977332T3 (cg-RX-API-DMAC7.html)
HU (1) HUE065844T2 (cg-RX-API-DMAC7.html)
IL (1) IL315136A (cg-RX-API-DMAC7.html)
MX (2) MX384192B (cg-RX-API-DMAC7.html)
PL (2) PL3973987T3 (cg-RX-API-DMAC7.html)
PT (2) PT3107575T (cg-RX-API-DMAC7.html)
RU (1) RU2713406C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015127229A1 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN104755495A (zh) 2012-08-21 2015-07-01 赛诺菲 通过施用il-4r拮抗剂治疗或预防哮喘的方法
RU2698907C2 (ru) 2012-09-07 2019-09-02 Ридженерон Фармасьютикалз, Инк. Способы лечения атопического дерматита с помощью антагониста il-4r
TWI633891B (zh) * 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
PL3010539T3 (pl) 2013-06-21 2020-01-31 Sanofi Biotechnology Sposoby leczenia polipowatości nosa przez podawanie antagonisty il-4r
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
EP3838271B1 (en) 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
MX376691B (es) 2014-02-28 2025-03-07 Regeneron Pharma Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
KR20230158131A (ko) 2014-11-14 2023-11-17 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
PT3506931T (pt) 2016-09-01 2024-08-21 Regeneron Pharma Métodos de prevenção ou de tratamento da alergia mediante a administração de um antagonista de il-4r
RU2759630C2 (ru) 2016-09-22 2021-11-16 Ридженерон Фармасьютикалз, Инк. Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
CN110431240A (zh) * 2017-04-13 2019-11-08 雷杰纳荣制药公司 在编码il33和il1rl1的基因中具有风险等位基因的患者的炎症性肺部疾病的治疗和抑制
EP3645009A4 (en) 2017-06-27 2021-03-31 The Ohio State Innovation Foundation LIPONUCLEOTIDE THERAPY FOR COPD
US11850283B2 (en) 2017-06-27 2023-12-26 Ohio State Innovation Foundation Liponucleotide-based therapy for asthma
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
KR102694419B1 (ko) * 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
SG11202009371WA (en) 2018-05-13 2020-10-29 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r inhibitor
EP3820891A1 (en) * 2018-07-10 2021-05-19 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-existing interactions
CN110872349A (zh) 2018-09-04 2020-03-10 三生国健药业(上海)股份有限公司 结合人il-4r的抗体、其制备方法和用途
CN111514292B (zh) 2018-12-25 2023-06-20 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
JP7759255B2 (ja) * 2018-12-27 2025-10-23 中山康方生物医▲藥▼有限公司 ヒトil4raに対する抗体及びその使用
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
TWI894144B (zh) * 2019-05-01 2025-08-21 法商賽諾菲生物技術公司 藉由投予il-33拮抗劑治療或預防哮喘之方法
US12398212B2 (en) 2019-07-16 2025-08-26 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
JP2023504204A (ja) 2019-12-09 2023-02-01 サノフィ・バイオテクノロジー デジタル的に識別されたil-4/il-13関連障害を治療する方法
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CN113797331A (zh) * 2020-06-16 2021-12-17 三生国健药业(上海)股份有限公司 一种稳定的抗IL-4Rα单克隆抗体液体制剂
KR20230067604A (ko) * 2020-08-05 2023-05-16 아레테이아 테라퓨틱스, 인코포레이티드 중등도 내지 중증 천식의 치료를 위한 덱스프라미펙솔의 용도
BR112023004020A2 (pt) * 2020-10-05 2023-04-25 Sanofi Biotechnology Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
US20240343815A1 (en) * 2021-08-26 2024-10-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition of anti-il4r antibody and use thereof
CN117368487A (zh) * 2023-09-28 2024-01-09 首都医科大学附属北京同仁医院 一种利用局部IgE预测或评估奥马珠单抗在治疗复发性鼻息肉中疗效的方法和应用
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP2292665B1 (en) 2000-05-26 2015-07-08 Immunex Corporation Use of interleukin-4 antibodies and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
TWI356064B (en) 2003-11-07 2012-01-11 Immunex Corp Antibodies that bind interleukin-4 receptor
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il−4/il−13特異的ポリペプチドおよびその治療上の使用
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
CA2636854A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
CN101454345B (zh) 2006-06-02 2012-08-08 瑞泽恩制药公司 人il-6受体的高亲和力抗体
DK2769992T3 (da) 2006-10-02 2021-03-22 Regeneron Pharma Humane antistoffer med høj affinitet for human IL-4-receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
DK2245064T3 (da) * 2007-12-21 2014-10-27 Medimmune Ltd BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa)
US20120004205A1 (en) 2008-12-01 2012-01-05 Cincinnati Children's Hospital Medical Center Il-13 induced gene signature for eosinophilic esophagitis
EP2414520A2 (en) 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
US20130281876A1 (en) * 2010-10-15 2013-10-24 Medimmune Limited Therapies for improving pulmonary function
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
RU2014122189A (ru) * 2011-11-01 2015-12-10 МЕДИММЬЮН, ЭлЭлСи Способы снижения частоты и тяжести острых приступов астмы
CN104755495A (zh) * 2012-08-21 2015-07-01 赛诺菲 通过施用il-4r拮抗剂治疗或预防哮喘的方法
RU2698907C2 (ru) 2012-09-07 2019-09-02 Ридженерон Фармасьютикалз, Инк. Способы лечения атопического дерматита с помощью антагониста il-4r
PL3010539T3 (pl) 2013-06-21 2020-01-31 Sanofi Biotechnology Sposoby leczenia polipowatości nosa przez podawanie antagonisty il-4r
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
KR20230158131A (ko) 2014-11-14 2023-11-17 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
KR102694419B1 (ko) * 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
BR112023004020A2 (pt) 2020-10-05 2023-04-25 Sanofi Biotechnology Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r

Similar Documents

Publication Publication Date Title
JP2017507139A5 (cg-RX-API-DMAC7.html)
RU2016136364A (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-4r
JP2023162343A5 (cg-RX-API-DMAC7.html)
JP2009541374A5 (cg-RX-API-DMAC7.html)
JP2021501169A5 (cg-RX-API-DMAC7.html)
JP2018512435A5 (cg-RX-API-DMAC7.html)
CA2918105C (en) Methods for reducing exacerbation rates of asthma using benralizumab
JP2014533279A5 (cg-RX-API-DMAC7.html)
JP2015527364A5 (cg-RX-API-DMAC7.html)
RU2017120437A (ru) Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r
IL273678B2 (en) Methods for treating allergy and improving allergen-specific immunotherapy by administering an IL-4R inhibitor
JP2016523863A5 (cg-RX-API-DMAC7.html)
JP2017535547A5 (cg-RX-API-DMAC7.html)
RU2018131237A (ru) Способы лечения атопического дерматита с помощью антагониста il-4r
RU2012141556A (ru) Способы и композиции для лечения болезни дего
JP2009511480A5 (cg-RX-API-DMAC7.html)
JP2017537105A5 (cg-RX-API-DMAC7.html)
JP2019512472A5 (cg-RX-API-DMAC7.html)
JP2019529560A5 (cg-RX-API-DMAC7.html)
JP2018515513A (ja) 多発性骨髄腫(mm)の処置
RU2019111921A (ru) Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
JP7572041B2 (ja) 重症喘息を処置するための組成物および方法
EP3487881A1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2025072440A5 (cg-RX-API-DMAC7.html)
TW202207976A (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合